Skip to content
DaveManuel.com · Institutional Ownership · 13F Holdings

PSP Research LLC

Reported holdings as of Q3 2026, from 4 quarterly filings.

CIK
2106939
Reported value
$145.8M
Positions
44
Top 10 weight
95.0%
Filed
2026-10-21
Days after quarter end
21

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
ISHARES TRSGOV$70.5M700,00048.33%+10.82pp4qHELD
SPDR SERIES TRUSTXBI$60.9M386,50041.79%-6.22pp3q-32.2%-$28.9M
Sera Prognostics, Inc.SERA$5.0M2,396,6853.43%-newNEW
HALOZYME THERAPEUTICS INCHALO$331.2K3,0000.23%-0.06pp4q-57.1%-$441.6K
MADRIGAL PHARMACEUTICALS INCMDGL$302.4K6000.21%+0.04pp4qHELD
EXELIXIS INCEXEL$292.1K5,0000.20%-0.03pp4q-37.5%-$175.2K
ROYALTY PHARMA PLCRPRX$291.8K5,0000.20%-0.13pp4q-54.5%-$350.2K
ARGENX SEARGX$287.7K3000.20%-0.12pp4q-53.2%-$327.0K
NURIX THERAPEUTICS INCNRIX$284.5K12,0000.20%-0.13pp4q-52.0%-$308.2K
TG THERAPEUTICS INCTGTX$278.9K5,0000.19%-0.10pp4q-50.0%-$278.9K
TARSUS PHARMACEUTICALS INCTARS$275.1K3,5000.19%-0.05pp4q-50.0%-$275.1K
HARMONY BIOSCIENCES HLDGS INHRMY$274.8K7,0000.19%-0.01pp4q-30.0%-$117.8K
ARCUTIS BIOTHERAPEUTICS INCARQT$264.3K10,0000.18%-0.09pp4q-49.2%-$256.4K
KINIKSA PHARMACEUTICALS INTLKNSA$261.1K3,5000.18%+0.01pp4q-30.0%-$111.9K
SUPERNUS PHARMACEUTICALSSUPN$258.2K6,0000.18%+0.03pp4qHELD
IMMUNOME INCIMNM$258.1K12,0000.18%-0.03pp4q-33.3%-$129.1K
NEUROCRINE BIOSCIENCES INCNBIX$255.3K1,8000.18%-0.09pp4q-40.0%-$170.2K
ORUKA THERAPEUTICS INCORKA$249.9K3,0000.17%+0.02pp3qHELD
TANGO THERAPEUTICS INCTNGX$249.5K10,0000.17%flat3qHELD
DEFINIUM THERAPEUTICS INCDFTX$247.4K6,5000.17%-0.08pp3q-35.0%-$133.2K
REVOLUTION MEDICINES INCRVMD$246.3K1,2000.17%+0.05pp2qHELD
ALKERMES PLCALKS$243.1K6,0000.17%flat4qHELD
AURINIA PHARMACEUTICALS INCAUPH$242.9K15,0000.17%-0.10pp4q-50.0%-$242.9K
INCYTE CORPINCY$242.7K2,0000.17%-0.15pp4q-62.3%-$400.5K
INTELLIA THERAPEUTICS INCNTLA$241.2K20,0000.17%-0.01pp3qHELD
IMMUNOVANT INCIMVT$236.5K7,0000.16%-0.10pp4q-46.2%-$202.7K
STOKE THERAPEUTICS INCSTOK$234.0K9,0000.16%-0.05pp4q-25.0%-$78.0K
KRYSTAL BIOTECH INCKRYS$230.1K6920.16%+0.02pp2qHELD
ASCENDIS PHARMA A/SASND$227.8K1,0000.16%-0.06pp2q-33.3%-$113.9K
SYNDAX PHARMACEUTICALS INCSNDX$225.6K12,0000.15%-0.08pp4q-40.0%-$150.4K
KYMERA THERAPEUTICS INCKYMR$223.6K2,0000.15%-0.09pp4q-50.0%-$223.6K
DIANTHUS THERAPEUTICS INCDNTH$220.1K2,5000.15%+0.02pp4qHELD
TREVI THERAPEUTICS INCTRVI$214.8K15,0000.15%-0.15pp3q-50.0%-$214.8K
MIRUM PHARMACEUTICALS INCMIRM$213.7K2,5000.15%-0.01pp4qHELD
IMMUNOCORE HLDGS PLCIMCR$212.0K7,0000.15%-0.11pp4q-53.8%-$246.6K
PROTAGONIST THERAPEUTICS INCPTGX$211.3K1,5000.14%-0.05pp4q-50.0%-$211.3K
EDGEWISE THERAPEUTICS INCEWTX$203.0K5,0000.14%+0.03pp3qHELD
ORIC PHARMACEUTICALS INCORIC$175.1K13,0000.12%+0.05pp3qHELD
DYNE THERAPEUTICS INCDYN$161.1K10,0000.11%-0.13pp4q-50.0%-$161.1K
COMPASS PATHWAYS PLCCMPS$124.4K10,0000.09%-0.05pp3q-44.4%-$99.5K
OCULAR THERAPEUTIX INCOCUL$115.0K15,0000.08%flat4qHELD
CYTOMX THERAPEUTICS INCCTMX$107.2K39,4000.07%-0.01pp2qHELD
ARDELYX INCARDX$102.6K30,0000.07%-0.09pp3q-50.0%-$102.6K
OLEMA PHARMACEUTICALS INCOLMA$86.4K10,0000.06%-0.01pp4qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 6.4%Healthcare Services 3.4%Not classified 90.1%
 
SectorValueShare
Biotech & Pharma$9.4M6.4%
Healthcare Services$5.0M3.4%
Not classified$131.4M90.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q3 2026-1.7%+2.1%-3.8%100%
Q2 2026+10.8%+14.8%-4.0%100%
Q1 2026+1.7%-4.6%+6.4%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q3 2026$145.8M4410273295.0%21
Q2 2026$187.9M75111301588.0%9
Q1 2026$141.3M79219402781.9%17
Q4 2025$114.4M85000065.8%37

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.